Leo F Buckley1, Dave L Dixon1, George F Wohlford1, Dayanjan S Wijesinghe1, William L Baker2, Benjamin W Van Tassell3. 1. Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA. 2. Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, CT. 3. Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA bvantassell@vcu.edu.
Abstract
OBJECTIVE: We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS: This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM. RESULTS: The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (P < 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96; P = 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93; P = 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%; P = 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (P > 0.62). CONCLUSIONS:Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.
RCT Entities:
OBJECTIVE: We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS: This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The "SPRINT-eligible" ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM. RESULTS: The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (P < 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65-0.96; P = 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51-0.93; P = 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%; P = 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (P > 0.62). CONCLUSIONS: Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.
Authors: Srinivasan Beddhu; Tom Greene; Robert Boucher; William C Cushman; Guo Wei; Gregory Stoddard; Joachim H Ix; Michel Chonchol; Holly Kramer; Alfred K Cheung; Paul L Kimmel; Paul K Whelton; Glenn M Chertow Journal: Lancet Diabetes Endocrinol Date: 2018-04-21 Impact factor: 32.069
Authors: Holly J Kramer; Raymond R Townsend; Karen Griffin; Joseph T Flynn; Daniel E Weiner; Michael V Rocco; Michael J Choi; Matthew R Weir; Tara I Chang; Rajiv Agarwal; Srinivasan Beddhu Journal: Am J Kidney Dis Date: 2019-04 Impact factor: 8.860
Authors: Jackson T Wright; Paul K Whelton; Karen C Johnson; Joni K Snyder; David M Reboussin; William C Cushman; Jeff D Williamson; Nicholas M Pajewski; Alfred K Cheung; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Srinivasan Beddhu; Lawrence J Fine; Jeffrey A Cutler; Walter T Ambrosius; Mahboob Rahman; Carolyn H Still; Zhengyi Chen; Curtis Tatsuoka Journal: Hypertension Date: 2021-11-10 Impact factor: 10.190
Authors: Faisal Rahman; John W McEvoy; Toshiaki Ohkuma; Michel Marre; Pavel Hamet; Stephen Harrap; Giuseppe Mancia; Anthony Rodgers; Elizabeth Selvin; Bryan Williams; Paul Muntner; John Chalmers; Mark Woodward Journal: Hypertension Date: 2019-06 Impact factor: 10.190